Keytruda®

Active substance pembrolizumab
Holder MSD Belgium BV/SRL
Status Closed
Indication in combination with chemotherapy with or without bevacizumab for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥1
Public documents Approbation
  Information for the patient
  Informed consent
Last update 09/08/2022

 

Last updated on 13/02/2024